PK150

PK150, an analogue of Sorafenib, shows oral bioavailability and antibacterial activity against several pathogenic strains at submicromolar concentrations. PK150 inhibits Gram-positive Methicillin-sensitive S. aureus (MSSA), Methicillin-resistant S. aureus (MRSA), Vancomycin intermediate S. aureus (VISA) with MICs of 0.3, 0.3-1, 0.3 μM, respectively[1].

Product Specifications

CAS Number

[2165324-62-7]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Bacterial

Type

Reference compound

Related Pathways

Anti-infection

Applications

COVID-19-immunoregulation

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/pk150.html

Purity

99.43

Solubility

DMSO : 250 mg/mL (ultrasonic)

Smiles

O=C(NC1=CC=C(OC(F)(F)O2)C2=C1)NC3=CC=C(Cl)C(C(F)(F)F)=C3

Molecular Formula

C15H8ClF5N2O3

Molecular Weight

394.68

Precautions

H302, H315, H319, H335

References & Citations

[1]Le P, et al. Repurposing human kinase inhibitors to create an antibiotic active against drug-resistant Staphylococcus aureus, persisters and biofilms. Nat Chem. 2019 Dec 16.